Physician Assistant in Glencoe, MN Accepting Medicare

4 Physician Assistant nurses found. Showing 1 - 4

Curtis Floyd Forst, MPA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1805 Hennepin Ave N, Glencoe, MN 55336 Phone: 320-864-3121    Fax: 320-864-7887

Ms. Patricia Jeanette De Loyal, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1805 Hennepin Ave N, Glencoe, MN 55336 Phone: 320-864-3121    Fax: 320-864-7998

Haley Kaye Wenner, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1805 Hennepin Ave N, Glencoe, MN 55336 Phone: 320-864-3121

Kari N Knodel-vettel, MPAS PAC Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1805 Hennepin Ave N, Glencoe Regional Health Services, Glencoe, MN 55336 Phone: 320-864-3121    Fax: 320-864-7887

News Archive

15,000 children and adolescents in the United States are diagnosed with type 1 diabetes annually

Approximately 15,000 children and adolescents in the United States are diagnosed with type 1 diabetes, and about 3,700 youth are diagnosed with type 2 diabetes annually, according to estimates from a major national study called SEARCH for Diabetes in Youth.

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

A team of Cedars-Sinai Heart Institute stem cell researchers led by Eduardo Marb-n, M.D., Ph.D. has been awarded a four-year, $5.5 million grant from the California Institute of Regenerative Medicine (CIRM) to fund research leading to clinical trials of new treatments for heart attack patients.

Genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for lung disease

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.

Read more Medical News

› Verified 3 days ago